Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12566909rdf:typepubmed:Citationlld:pubmed
pubmed-article:12566909lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:12566909lifeskim:mentionsumls-concept:C0205420lld:lifeskim
pubmed-article:12566909pubmed:issue2lld:pubmed
pubmed-article:12566909pubmed:dateCreated2003-2-4lld:pubmed
pubmed-article:12566909pubmed:abstractTextTo evaluate the efficacy and toxicity of concurrent administration of doxorubicin and docetaxel, without prophylactic use of granulocyte colony-stimulating factor, as first-line chemotherapy in patients with metastatic breast cancer (MBC).lld:pubmed
pubmed-article:12566909pubmed:languageenglld:pubmed
pubmed-article:12566909pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:citationSubsetIMlld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12566909pubmed:statusMEDLINElld:pubmed
pubmed-article:12566909pubmed:issn0030-2414lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:NoguchiShinza...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:SonooHiroshiHlld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:HorikoshiNobo...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:KatsumataNori...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:WatanabeToruTlld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:SasakiYasutsu...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:DEVEFFlld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:HirakiShunkic...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:TabeiToshioTlld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:TakatsukaYuic...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:AiharaTomohik...lld:pubmed
pubmed-article:12566909pubmed:authorpubmed-author:ItohKuniakiKlld:pubmed
pubmed-article:12566909pubmed:copyrightInfoCopyright 2003 S. Karger AG, Basellld:pubmed
pubmed-article:12566909pubmed:issnTypePrintlld:pubmed
pubmed-article:12566909pubmed:volume64lld:pubmed
pubmed-article:12566909pubmed:ownerNLMlld:pubmed
pubmed-article:12566909pubmed:authorsCompleteYlld:pubmed
pubmed-article:12566909pubmed:pagination124-30lld:pubmed
pubmed-article:12566909pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:meshHeadingpubmed-meshheading:12566909...lld:pubmed
pubmed-article:12566909pubmed:year2003lld:pubmed
pubmed-article:12566909pubmed:articleTitlePhase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.lld:pubmed
pubmed-article:12566909pubmed:affiliationDepartment of Surgery, Kansai Rosai Hospital, Hyogo, Japan. aiharat@kanrou.netlld:pubmed
pubmed-article:12566909pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12566909pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12566909pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12566909pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:12566909pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12566909lld:pubmed